Prime Medicine (PRME) Chardan 8th Annual Genetic Medicines Conference summary

Technology and platform overview

• Prime editing technology enables precise genetic corrections, advancing beyond traditional CRISPR methods.

• The platform supports a wide range of edits, from small to large, and is applicable in both in vivo and ex vivo settings.

• Four years of development have led to robust preclinical and early clinical progress.

Strategic collaboration and financial impact

• Announced a broad, strategic collaboration with BMS to develop next-generation CAR T therapies using prime editing.

• The deal includes $110 million upfront, $185 million in preclinical milestones, and up to $1.2 billion in development milestones.

• Collaboration extends financial runway into the first half of 2026.

• BMS will lead program development, with ongoing support in reagent development and preclinical work.

Pipeline prioritization and value framework

• Pipeline refocused to prioritize programs with the highest value and clinical tractability.

• Decision criteria included commercial opportunity, net present value, competitive landscape, and technical feasibility.

• Programs with longer timelines or lower feasibility, such as those targeting the brain, were deprioritized.

• Some deprioritized programs may be revisited or partnered in the future.